2026 Publications
Srour, N.;Luo, K.; Allard, D.; Xiong, Y.; Yu, Z.; Papadopoulos, T.; Santinon, F.; Hsieh, C; Parent, A.; Stagg, Z.; Turcotte, S; Barsyte-Lovejoy, D.; Lehoux, S.; Rincón, S. Jin, J.*; Richard, S*.; “PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway” , Nature Communications, 2026 Sept 6;. doi: https://doi.org/10.1038/s41467-026-77155-2
Song, X.; Wu, Q.; Chen, L.; Inuzuka, H.; Zhong, Y.; Qi, Y.; Lin, Y.; Kabir, M.; Xiong, Y.*; Wei, W.*; Jin, J.* “Discovery of New OTUB1 Covalent Ligands via Structure-Activity Relationship Studies for Targeted Protein Stabilization” , Journal of Medicinal Chemistry, 2026 May 4;. doi: https://doi.org/10.1021/acs.jmedchem.5c03327
Luo, K.; Xue, Z.; Qin, L.; Wang, Z.; Gao, P.; Xie, L.; Su, Y.; Chen, X.; Kaniskan, H. Ü.*; Wen, H.*; Jin, J.* “Discovery of a Highly Potent and Selective ENL Degrader” Journal of Medicinal Chemistry , 2026 Apr 23;. doi: 10.1021/acs.jmedchem.6c00386 doi:https//doi.org/10.1021/acs.jmedchem.6c00386.PMID: 42025203
Gao, P.; Zhong, Y.; Luo, K.; Jin, J.* “Bridged PROTAC, DNA-based PROTAC and hydrophobic tag technologies for targeted protein degradation” Advanced Drug Delivery Reviews , May, 2026, Volume 232, 115819. doi:https://doi.org/10.1016/j.addr.2026.115819. PMID: 41707939
Chen, H.; Dutta, R. P.; Li, Z.; Zhong, Y.; Ma, A.; Park, K. S.; Kottur, J.; Park, A.; Babault, N.; Wang, K.; Wang, D.; Xiong, Y.; Kaniskan, H. Ü.; Luo, M.; Parekh, S.; Jin, J.*, “Discovery of a Potent, Selective, and In Vivo Efficacious Covalent Inhibitor for Lysine Methyltransferase SETD8”, Journal of Medicinal Chemistry, Feb 16th, 2026, 4255-4269. doi:https://doi.org/10.1021/acs.jmedchem.5c02958 , PMID: 41693203
Yim, H.; Song, X.; Zhong, Y.; Hu, J.; Xiong, Y.; Jin, J.*, “Discovery of KRAS-G12D degraders via exploration of various E3 ligases”, European Journal of Medicinal Chemistry, April 5, 2026, Volumn 307, 118635. doi: https://doi.org/10.1016/j.ejmech.2026.118635, PMID:41679196 ,
Xia, Z.; Yang, X.; Samovich, S. N.; Tyurina, Y. Y.; Tyurin, V. A.; Kon, N.; Zhang, J.; Jiang, X.; Stockwell, B. R.; Jin, J.; Bayir, H.; Kagan, V. E.; Gu, W.*, “A GPX1–OSBPL8 Axis Mediates Noncanonical In Vivo Ferroptosis and Cancer Growth Suppression”, Cell , Feb 19, 2026, doi:https://doi.org/10.1016/j.cell.2026.01.009 PMCID: PMC12927606.
Wang, Y.; Xiong, Y.; Liu, S.; Bao, L.; Qiu, X.; Korboukh, I.; Song, X.; Toffessi Tcheuyap, V.; Wu, S.; Chen, M.; Brugarolas, J.; Jin, J.; Wang, Y.; Luo, W.*, “HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer”, Cell Reports Medicine, Feb 18, 2026; 102630. doi:https://doi.org/10.1016/j.xcrm.2026.102630
Yi, Y.; Li, Y.; Wang, R.; Yu, X.; Liu, Q.; Yum, C.; Zhang, Y.; Qiao, Y.; Szczepanski, A.; Wu, S.; Li, Q.; Fazli, L.; Shen, J.; Wang, X.; Li, X.; Mu, P.; Schaeffer, E. M.; Hundley, H. A.; Niu, H.; Chinnaiyan, A. M.; Wang, L.; Shi, J.; Jin, J.; Dong, X.; Zhao, W.; Chen, K.; Cao, Q.*, “A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR”, Nature Communications, march 26, 2026, PMID: 41882000
Yi, Y.; Fry, J.; Yum, C.; Wang, R.; Wu, S.; Narayan, S.; Liu, Q.; Zhang, X.; Oo, H. Z.; Xie, N.; Li, Y.; Gao, X.; Yu, X.; Hu, X.; Li, Q.; Keseroglu, K.; Özbudak, E. M.; Abdulkadir, S. A.; Chen, K.; Jin, J.; Zhao, J. C.; Dong, X.; Arango, D.; Yang, R.; Cao, Q.*, “EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of the m6A autoregulation pathway” Journal of Clinical Investigation, 2026, 136(2). doi: 10.1172/JCI195840. https://doi.org/10.1172/JCI195840 PMCID: PMC12807473. PMID: 41252201
2025 Publications
Selective 19 of total 30 of 2025 Publications
Hu, X.; Graciano, K.; Hu, J.; Liu, C.; Zhang, J.; Xie, L.; Chen, X.; Xiong, Y.; Jin, J.*; Xu, J.*, “Discovery of the first-in-class Aurora B kinase selective degrader”, European Journal of Medicinal Chemistry , 2025, 298, 118006. Volume 298, 15 November 2025, 118006. DOI: https://pubs.acs.org/doi/10.1021/jacs.5c06306
Chen, L; Deng, Z.; Xiong, Y.; Liu, J.; Huang, D.; Wang, J.; Chen, Y.; Inuzuka, H.; Xie, L.; Chen, X.; Jin, J.*; Wei, W.*, “Deubiquitinase-Targeting Chimeras Mediated Stabilization of Tumor Suppressive E3 Ligase Proteins as a Strategy for Cancer Therapy”, Journal of the American Chemical Society , 2025, 147,DOI: https://doi.org/10.1021/jacs.5c06306
Qian, C.; Wang, Z.; Xiong, Y.; Zhang, D.; Zhong, Y.;Inuzuka, H.; Qi, Y.; Xie, L.; Chen, X.; Wei, W.* ; Jin, J.* , “Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization”. Journal of the American Chemical Society , 2025, 147, 17, 14564–14573, doi: https://doi.org/https://doi.org/10.1021/jacs.5c01662
Zhong, Y.; Kim, H. S.; Qian, C.; Xie, L.; Chen, X.; Xiong, Y.; Hu, J.; Chen, M.; Guccione, E.; Shen, Y.*; Jin, J.* , “Discovery of A Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader”. Journal of Medicinal Chemistry, 2025, 68, 8, 8543–8563. doi: https://doi.org/https://doi.org/10.1021/acs.jmedchem.5c00198 .
Deng, Z.; Catlett, J.; Lee, Y.; Wu, Q.; Xu, Z.; Xie, L.; Chen, X.; Xiong, Y.; Kaniskan, H. U.*; Jin, J.*; “Harnessing the SPOP E3 Ubiquitin Ligase via Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation”, Journal of Medicinal Chemistry , 2025, 68, 8634–8647, doi: https://doi.org/10.1021/acs.jmedchem.5c00295
Yim, H.; Sun, R.; Xu, Z.; Kim, H. S.; Kim, M.; Cao, T.; Xie, L.; Chen, X.; Kaniskan, H. U.*; Jin, J.*; “Discovery of the First-in-class DOT1L PROTAC Degrader” European Journal of Medicinal Chemistry , Volume 291, 5 July, 117595, 2025. doi:https://https://doi.org/10.1016/j.ejmech.2025.117595;
Qian,C.; Lee,Y.; Han,Y.; Zhong,Y.; Zhou,J.; Hrit, J.; Xie,L.; Chen, Q.; Kaniskan, H. U.; Chen, X.; Rothbart, S.; Cheng, X.; Xiong, Y.*; Jin, J.* , “Structure-activity Relationship Studies of DNA Methyltransferase 1 (DNMT1) Monovalent Degraders”. Journal of Medicinal Chemistry, 2025, 68, 3, 2903–2919, doi:https://doi.org/10.1021/acs.jmedchem.4c02161; PMID: 39905966
Wang, S. E.; Cheng, Y.; Lim, J.; Jang, M.; Forrest, E.; Kim, Y.; Donahue, M.; Jo, S.; Qiao, S.; Lee, D. E.; Hong, J. Y.; Xiong, Y.; Jin, J.; Wang, S.; Jiang, Y. H.* “Mechanism of EHMT2-mediated genomic imprinting associated with Prader-Willi syndrome”. Nature Communications, 2025, 16:6125. PMCID: PMC12229668.
doi:
Zhu, S.; et al, Jin, J.; Luo, Z.* “Isoform-Specific Function of NSD3 in DNA Replication Stress Confers Resistance to PARP Inhibitors in Prostate Cancer”, Molecular Cell, 2025, DOI: https://doi.org/10.1016/j.molcel.2025.06.004
Haspula, D.; Cui, Z.; Pittala, S.; Cui, Y.; Lu, H.; Xiong, Y.; Jin, J.; Gavrilova, O.; Hwang, E.; Ajwani, J.; Portillo, B.; Williams, K. W.; Inoue, A.; Weiss, J.* “G proteins of the G12 family expressed by POMC neurons regulate key metabolic functions”, Science Advances, PMID: 40644553, PMCID: PMC12248387 , DOI: 10.1126/sciadv.adu1670
Yum, C.; Schaefer, R.; Wang, R.; Wang, T.; Lu, X.; Liu, Q.; Ren, Y.; Meng, Q.; Yang, Y.; Zhang, X.; Xiong, Y.; Yu, X.; Zhang, X.; Jin, J.; Dong, X.; Yi, Y.; Yang, R.; Cao, Q.* “Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2”, Oncogenesis PMID: 40651983, PMCID: PMC12255682
Dutta, R. P.; et al, Jin, J.; Alinari, L.; Wang, M.; Parekh, S.* , “SOX11 Modulates BCR Signaling Through the PAX5/CD19 Axis for Therapeutic Targeting in BTK Resistant Mantle Cell Lymphoma”, Blood Advances, 2025, PMID: 40845256, PMCID: PMC12744261
Deng, Z; Chen, L; Qian, C; Liu,J; Wu,Q; Song,X; Xiong,Y.; Wang, Z; Hu, X; Inuzuka, H; Zhong, Y; Lin; Y; Pham, N.D.; Shi,Y; Wei ;W.*; Jin,J.* Angewandte Chemie International Edition, “The First-in-class Deubiquitinase-targeting Chimera Stabilizes and Activates cGAS.”,2025 Jan 15;64(3):e202415168.; e202415168. doi: 10.1002/anie.202415168 PubMed PMID: 39150898.
Kabir. M.; Hu, X. Martin, T. C.; Pokushalov, D.; Kim, Y. J.; Chen, Y.; Zhong, Y.; Wu, Q; Chipuk, J. Y.; Shi, Y; Xiong, Y.; Gu, W.; Parsons, R. E.; and Jin, J.* , “Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53”, Advanced Science, 2025, PMID: 39716936. PMCID: PMC11831463, doi: http://doi.org/10.1002/advs.202413377
Wang, Z.; Qian, C.; Xiong, Y.; Zhang, D.; Inuzuka, H.; Zhong, Y.; Xie, L.; Chen, X.; Jin, J.*; Wei, W.*, “USP28-Based Deubiquitinase-Targeting Chimeras for Cancer Treatment”, Journal of the American Chemical Society,2025, 147, 16, 13754–13763. Published April 11, 2025. doi:https://doi.org/https://doi.org/10.1021/jacs.5c01889
Zhu, Z.; Chen, H.; Qiu, X.; Kaniskan, H. Ü.; Xie, L.; Chen, X.; Jin, J.*; Liu, P.* “(GGAA)3-based TF-PROTACs enable targeted degradation of ETV6 to inhibit Ewing sarcoma growth”, Journal of the American Chemical Society, April, 11, 2025, 147, 16, 13396–13404. doi: https://doi.org/https://doi.org/10.1021/jacs.4c18484
Teichman , E. M.; Hu , J.; in, H.; Fisher, R. F.; Blando, A.; Hu, X.; Kaniskan , H. U; Montgomery, S. E.; Cai, M.; Parise, L.; Wang, J.; Russo, S.; Han, M.*; Jin , J.*; Morel, C.* , “Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype ”. Molecular Psychiatry, April, 08,2025.PMID: 40199995, doi: https://doi.org/10.1038/s41380-025-02972-8
Xie, L.; Sheehy, R. N.; Xiong, Y.; Muneer, A.; Wrobel, J. A.; Park, K. S. ; Velez, J.; Liu, J.; Luo, Y. J.; Li , Y.; Quintanilla, L.; Li, Y.; Xu, C.; Deshmukh, M.; Wen, Z., Jin, J.*; Song, J.*; Chen, X.* , “A brain-penetrant G9a methylase inhibitor blocks Alzheimer’s disease proteopathology for the disease therapeutics.” Nature Communications, 16, Article number: 4222 (2025) , doi:
Yu, Y.; Yu, X.; Pan, B.; Chan, H. M.; Kaniskan, H. Ü.; Jin, J.; Cai, L.*; Wang, G. G.*, “Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma”. Science Advances , Apr,23, 2025.Vol 11, Issue 17. doi: https://doi.org/10.1126/sciadv.ads7876, PMID:23297491
2024 Publications
Selective 10 of total 15 of 2024 Publications
Kabir. M.; Hu, X. Martin, T. C.; Pokushalov, D.; Kim, Y. J.; Chen, Y.; Zhong, Y.; Wu, Q; Chipuk, J. Y.; Shi, Y; Xiong, Y.; Gu, W.; Parsons, R. E.; and Jin, J.* Advanced Science., “Harnessing the TAF1 Acetyltransferase for Targeted Acetylation of the Tumor Suppressor p53”, 2024, doi: http://doi.org/10.1002/advs.202413377
Martinez, Criseyda; Xiong, Yan; Bartkowski, Alison; Harada, Ibuki; Ren, Xiaoxiao; Byerly, Jessica; Port, Elisa; Jian Jin*; Irie, Hanna*. Cell Chemical Biology, “A PROTAC degrader suppresses oncogenic functions of PTK6 inducing apoptosis of breast cancer cells”, 2024, doi: https://doi.org/10.1016/j.chembiol.2024.10.008; PMID: 39541980
Inuzuka, H; Qian, Chao; Qi,Y; Xiong, Y; Wang, C;Wang,Z; Zhang, D;Zhang, C; Jin, J*; Wei, W*; ACS Pharmacology & Translational Science , “Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway”, https://doi.org/10.1021/acsptsci.4c00421 2024, 7, 3518-3526.
Corbin, J.; Yu, X.; Cai, L.; Jin, J.; Wang, G. G.* Oncogene , “EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth”, 2024, 43, 2722-2736. PMID:39112519
Xue Z; Qin L; Xuan H; Luo K; Huang M; Xie L; Su Y; Xu L; Harsh J; Dale B; Shi X; Chen X; Kaniskan HÜ; Jin J; *. , Wen H.*, “A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression.”.
Science Advances, 2024 Aug 30;10(35):eado1432. doi: 10.1126/sciadv.ado1432. Epub 2024 Aug 28. PMID:39196923. PMCID: PMC11352836.
Graboski, A.L.;Simpson,J.B.; Pellock;S.J.; Mehta, N.; Creekmore, B.C.; Ariyarathna; Y. ;Bhatt, A.P.; Jariwala,P.B.; Sekela, J.J.; Kowalewski, M.E.; Barker, N.K.; Mordant, A.L.; Borlandelli, V.B.; Overkleeft, H.; Herring, L.E.; Jin, J.*. ; I James L, Redinbo,M.R.. RSC Chemical Biology Journal, “Advanced piperazine-containing inhibitors target microbial β-glucuronidases linked to gut toxicity.” PMID:39211470 ; PubMed Central PMCID: PMC11353122. RSC Chemical Biology. 2024 Jul 16;5(9):853-865
Hu,X; Kabir, M; Lin, Y; Xiong Y; Parsons, R; Gu, W; Jin, J*“Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)”, Journal of Medicinal Chemistry, August, 2024.
Wang, S, E.; Xiong, Y.; Jang, M, A,; Park, K, S.; Donahue, M.; Velez J.; Jin J.*; Jiang, Y, H.*, “Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome”, Molecular Therapy, 2024, PMID:38796700. doi: 10.1016/j.ymthe.2024.05.034.
Kabir, M.; Qin, L.; Luo, K.; Xiong, Y.; Sidi, R. A.; Park, K.-S.*; Jin, J.*, Discovery and characterization of a novel Cereblon-recruiting PRC1 bridged PROTAC degrader. Journal of Medicinal Chemistry. 2024, 67(8):6880-6892. PMID: 38607318.
Velez, J.; Han, Y.; Yim, H.; Yang, P.; Deng, Z.; Park, K.-s.; Kabir, M.; Kaniskan, H. Ü.; Xiong, Y.*; Jin, J.*, Discovery of the first-in-class G9a/GLP PROTAC degrader. Journal of Medicinal Chemistry. 2024, 67(8):6397-6409. PMID: 38295690.
Kim, Y.; Gumpper, R. H.; Liu, Y.; Kocak, D. D.; Xiong, Y.; Cao, C.; Deng, Z.; Krumm, B. E.; Jain, M. K.; Zhang, S.; Jin, J.; Roth, B. L., Bitter taste receptor activation by cholesterol and an intracellular tastant. Nature 2024, 628(8008):664-671. PMID: 38600377.
Liu, J.; Hu, X.; Luo, K.; Xiong, Y.; Chen, L.; Wang, Z.; Inuzuka, H.; Qian, C.; Yu, X.; Xie, L.; Muneer, A.; Zhang, D.; Paulo, J. A.; Chen, X.; Jin, J.*; Wei, W.*, USP7-based deubiquitinase-targeting chimeras stabilize AMPK. Journal of the American Chemical Society. 2024,146, 16, 11507–11514. PMID:38597345.
Xiong, Y.; Greschik, H.; Johansson, C.; Seifert, L.; Gamble, V.; Park, K.-s.; Fagan, V.; Li, F.; Chau, I.; Vedadi, M.; Arrowsmith, C. H.; Brennan, P.; Fedorov, O.; Jung, M.; Farnie, G.; Liu, J.; Oppermann, U. *; Schüle, R. *; Jin, J. *, Discovery of a potent, selective, and cell-active SPIN1 inhibitor. Journal of Medicinal Chemistry. 2024, 67(7):5837-5853. PMID: 38533580.
Wang, Z.; Zhang, D.; Qiu, X.; Inuzuka, H.; Xiong, Y.; Liu, J.; Chen, L.; Chen, H.; Xie, L.; Kaniskan, H. Ü.; Chen, X.; Jin, J. *; Wei, W. *, Structurally specific Z-DNA proteolysis targeting chimera enables targeted degradation of adenosine deaminase acting on RNA 1. Journal of the American Chemical Society. 2024, 146 (11): 7584-7593. PMID: 38469801.
Velez, J.; Dale, B.; Park, K.-S.; Kaniskan, H. Ü.; Yu, X. *; Jin, J. *, Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2. European Journal of Medicinal Chemistry. 2024, 267, 116154 PMID: PMID: 38295690.
For papers published before 2023, please see Dr. Jin’s full publication list
Jin Lab Full Publication List
Posted on: Sept 15, 2026